FindTrial
Sign In

Treatment result and mode of action of topical drug called Diphencyprone in patchy hair loss called alopecia areata

Therapeutic outcome of Diphencyprone and its correlation with lesional immune cell subtypes and serum cytokine profile in alopecia areata-A pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/10/010109
Enrollment
40
Registered
2017-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Alopecia areata

Interventions

None listed

Sponsors

JIPMER intramural grant
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Extensive alopecia areata(more than 30 percent scalp hair loss)

Exclusion criteria

Exclusion criteria: 1.Patients who have taken any systemic or topical therapy in the last 1 month 2.Concomitant serious intercurrent illness 3.Liver failure 4.Significant cardiovascular disease 5.Pregnant and lactating women 6.Women of child-bearing potential not using contraception 7.Past or current history of tobacco or alcohol use

Design outcomes

Primary

MeasureTime frame
To study the therapeutic outcome of diphencyprone in extensive alopecia areataTimepoint: 6 months—

Secondary

MeasureTime frame
1.To study the lesional cell subtypes and serum cytokine profile in patient with alopecia areata 2.To study the clinical correlation of cytokines of T-helper and regulatory T cells and lesional immune cell types on treatment with diphencyproneTimepoint: 1. At baseline 2. At baseline and 6 months—

Countries

India

Contacts

Public ContactDr P M Rakhavi

JIPMER

laxmishac@gmail.com9894119058

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026